Plasma microRNAs biomarkers in mild cognitive impairment among patients with type 2 diabetes mellitus.

OBJECTIVES: To assess the potential value of some miRNAs as diagnostic biomarkers for mild cognitive impairment (MCI) among patients with type2 diabetes mellitus (T2DM) and to identify other risk factors for MCI among them.
METHODS: This study enrolled 163 adults with T2DM using face to face interview. Cognitive function with its domains was assessed using Adenbrooke's Cognitive Examination III (ACE III). Lipid profile, glycated hemoglobin, and miR-128, miR-132, miR- 874, miR-134, miR-323, and miR-382 expressions, using quantitative real-time PCR, were assessed.
RESULTS: MCI was detected among 59/163 (36.2%) patients with T2DM. Plasma expression of miR-132 was significantly higher in T2DM patients with MCI compared to those without MCI and to normal cognitive healthy individuals (median = 2, 1.1 and 1.2 respectively, P < 0.05. Logistic regression analysis showed that higher miR-132 expression with adjusted odds ratio (AOR): 1.2 (95% CI 1.0-1.3), female gender (AOR:2.1; 95%CI 1.0-4.3), education below postgraduate (secondary and university education with AOR: 9.5 & 19.4 respectively) were the significant predicting factors for MCI among T2DM patients. Using ROC curve, miR-132 was the only assayed miRNA that significantly differentiates T2DM patients with MCI from those with normal cognition with 72.3% sensitivity, 56.2% specificity, and 63.8% accuracy (P < 0.05). Other studied miRNAs showed lower sensitivity and specificity for detecting MCI among studied T2DM participants.
CONCLUSION: MCI affects nearly one-third of adult patients with T2DM. A significantly over expression of miR-132 was detected among T2DM with MCI compared to those with normal cognition.

Introduction

Type 2 diabetes mellitus (T2DM) is a major health problem all over the world and its incidence is rapidly increasing. Adverse effects of diabetes on cognitive function and memory disorders have been reported by researchers for a long time [1]. Diabetic patients are at higher risk for dementia, Alzheimer disease (AD), and vascular dementia than people with normal glucose tolerance [2]. The presentation of cognitive impairment ranges from subtle executive dysfunction to memory loss and overt dementia. Mild cognitive impairment (MCI) is of particular interest because of its influence on self-care and quality of life and its increased risk to progress to dementia including AD. Moreover, the prognosis of MCI among diabetics is worse than among non diabetics [2,3].

Glycemic control, hypoglycemia, dyslipidemia, micro and macrovascular complications have been reported as risk factors for cognitive dysfunction in T2DM but each appears to have limited effects [4]. On the other hand studies reported that intensive control of blood glucose, blood pressure, or cholesterol levels in T2DM is not beneficial in preventing cognitive decrements [5]. There are still substantial knowledge gaps on how the risk factors interact and affect cognition and the potential of the presence of genetic factors [6]. microRNAs (miRNAs) are widely distributed within the nervous system. They are key regulators of many biological functions such as neurogenesis, dendritic spine morphology, and synaptic plasticity. Moreover there is increasing evidence for their role in neurodegenerative disorders [7]. Many studies investigated the correlation of miRNAs dysregulation with AD. Butovsky and co-workers [8] observed the presence of miR-132 in all of the cell populations of the CNS with the strongest expression in the neurons, followed by astrocytes, oligodendrocytes, and finally, microglia. Moreover, miR-128, miR-132, and miR- 874 paired with miR-491, while miR-134, miR-323, and miR-382 paired with miR-370 have been validated as sensitive biomarkers for detection of MCI [9]. The scientific interest in miRNAs come from their potential value as disease biomarkers and as a molecular target of disease therapies [10].

The present study aimed at assessing the potential value of miR-128, miR-132 and miR- 874, miR-134, miR-323, and miR-382 as diagnostic biomarkers for MCI among a sample of Egyptian T2DM patients and the impact of the conventional risk factors on MCI among these patients.

Materials and methods

This study was conducted along one year (from June 2016 to December 2017). It involved 163 T2DM patients, 65 males and 98 females; aged from 40 to 60 years from outpatient clinics of Medical Services Unit of the National Research Center (NRC). Patients were already diagnosed as T2DM and were receiving anti-diabetics drugs, either insulin or oral hypoglycemic drugs. All patients were literate and were able to complete the tests of cognitive function. T2DM patients with history of head trauma, stroke, transient ischemic attack, brain tumor, epilepsy, psychiatric disease, cardiac or liver failure, history of thyroid disease, visual or hearing disabilities, and acute or chronic infection were excluded. Inorder to compare the miRNAs expressions among T2DM patients to normal cognitive non T2DM individuals, 109 non diabetic apparently healthy normal cognition individuals (age, sex, and education matched to the studied T2DM patients) were participated.

The study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). Each participant provided an informed written consent after acknowledgement about the research. The study was approved by the Medical Research Ethical Committee of the NRC {registration number 15131}. A face to face interview was carried out where a closed ended questionnaire module was used to cover data on demographic characteristics and full medical history. Data included age, gender, level of education, and tobacco smoking. Detailed medical history of diabetes was taken from the patients including age at detecting T2DM, number and frequency of hypoglycemic events, type of treatment taken for diabetes (insulin or oral hypoglycemic drugs), history of hypertension, dyslipidemia, history of other diseases, and medications taken. Any complaint suggestive the presence of sensory peripheral neuropathy such as tingling, burning pain or numbness in hands and feet was recorded. All the studied participants were subjected to thorough clinical examination with anthropometric assessment (weight and height measurements) and body mass index (BMI) was calculated as weight in kg/height in m2. Obesity was defined as BMI ≥ 30kg/m2. Hypertension was defined as blood pressure above 140/90 or patients on anti-hypertensive medications. Peripheral sensory neuropathy was diagnosed by history and positive pinprick and/or filament test.

Assessment of cognitive function with its domains

The case definition of MCI was based on the objective impairment in one or more cognitive domains. Adenbrooke’s Cognitive Examination III (ACE III) test was chosen to assess global and specific cognitive domains. It is the most reliable and validated Arabic form cognitive scale and freely available to be applied. Objective MCI was considered if ACE III score is less than 88 Preservation of independence in daily functional abilities using SF36 quality of life was used to exclude dementia [11].

Laboratory analysis

Venous blood samples after an overnight fast (12 hours) were withdrawn from all participants. Part of the blood sample was anticoagulated with EDTA for assessment of the glycated hemoglobin (HbA1c) (using Labona check™ HbA1c analyzer) and for measurement of selected miRNAs by real-time PCR. The other part of blood sample was left to clot and sera were separated immediately for analysis of lipid profile by Erba xl -300 Mannheim Gmbh Germany. Patients were diagnosed to have dyslipidemia if total cholesterol is above 200mg/dl and/or triglycerides above 150 mg/dl or patient on anti- hyperlipidemic drugs.

miRNA gene expression

Blood samples were collected in EDTA-containing vacutainer. After 20 min centrifugation (2500×g), plasma was separated, aliquoted and stored at − 80 °C until used. Plasma samples were thawed on ice for RNA extraction. RNA was isolated from 200 μL of plasma, using the miRNeasy RNA isolation kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. The concentration and purity of isolated RNA were evaluated by NanoDrop 1000 (Nanodrop, Wilmingtion, Delaware, USA) using 1 μl of RNA based on the absorbance measurements at wavelengths of 260 and 280 nm. Samples with 260/280 ratios of ~2.0 is generally accepted as “pure” for RNA. Then, 2 μl of RNA were reverse-transcribed to cDNA using TaqMan™ Advanced miR cDNA Synthesis Kit, Catalog Number A25576). (Applied Biosystems, Foster City, CA, USA).

Quantitative real-time PCR (RT-qPCR) assay was carried out with a 1.5-mL microcentrifuge from 5 μL of 1/10 diluted cDNA (plasma samples) using 10 μL TaqMan Fast Advanced Master Mix, 1 μL TaqMan Advanced miRNA Assays (Applied Biosystems, Foster City, CA, USA) and 4 μL RNase-free water. The total volume of the mixture product for PCR was 20 μl. The incubation of the mixture product was carried out at 95°C for 20 seconds followed by 40 cycles of Denature at 95°C for 1s and Anneal / Extend at 60°C for 20 seconds.

Real-time quantitative PCR was performed using the Quantistudio 12Kflex Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Samples were run in duplicate and internal control samples were repeated in every plate to avoid batch effect. The results were analyzed using the RQ manager software (Applied Biosystems). miR-491 was used as normalizer for miR-128, miR-132 and mir-874, while miR-370 was used as normalizer for miR-134, miR-323 and miR-382 according to Sheinerman and co-workers [9]. The expression levels of miRNAs were calculated using the 2-ΔΔCt method.

Statistical analysis

Statistical program for social science (SPSS) version 18 for windows SPSS; Inc, Chicago IL was used for data analysis. Chi square test was used for comparing between two qualitative variables. T-test was used for comparing between two means. When data were not normally distributed Mann-Whitney U-tests were used. For comparing between 3 groups, Kruskal Wallis test was used. Two multivariate logistic analyses models were carried out for predicting the convential risk factors and the miRNAs expressions that are significantly associated with MCI among T2DM patients. P < 0.05 was considered statistically significant and p < 0.01 was considered statistically highly significant. For evaluating the diagnostic performance of each miRNAs, Receiver-Operating Characteristic (ROC) analysis was carried out for obtaining the area under the curve (AUC) and the corresponding 95% CI. The maximum diagnostic discrimination (MDD) cut-off point was calculated, corresponding to the highest Youden index for each miRNA, followed by detecting the sensitivity, specificity and accuracy for each miRNA were calculated for the identified “cutoff” points.

Results

The study included 163 T2DM patients aged between 40 and 60 years with mean 53.2 ±5.3 years; 65 (39.9%) of them were males. Non-diabetic normal cognitive 109 individuals were aged between 40–60 years (mean: 51.9 ±4.5 years); 43 (39.4%) of them were males, P > 0.05. The percentages of T2DM patients having secondary, university and post graduate education were 46%, 39.9%, and 14.1% compared to 41.3%, 42.2% and 16.5% respectively among non diabetic normal cognitive individuals, P = 0.716. Thirty-two (19.6%) of T2DM patients were taking insulin and the rest were taking oral hypoglycemic drugs in the form of sulfonylurea and/or metformin. The ACE III score ranged from 69 to 100 with mean 88.8 ± 6.1. According to ACE III, MCI was present among 59 (36.2%) of the studied T2DM patients. The mean score of ACE III was significantly lower among T2DM patients with MCI (81.5±4.5) compared to those with normal cognition (91.5±3.1), P < 0.001. While, the mean score of ACE III was significantly higher among cognitive normal individuals (93.7 ± 3.0) compared the T2DM patients with and without MCI, P < 0.001.

Expressions of miRNAs among non diabetic normal cognitive individuals and T2DM patients with and without MCI

The median miR-132 expression was significantly higher among T2DM patients with MCI compared to those with normal cognition as well as normal non-diabetic cognitive individuals, P< 0.05. While the median miR-874 expression was significantly higher among T2DM patients with and without MCI compared to non diabetic normal cognitive individuals, (P< 0.001). While, miR-128, miR-134, miR-323, and miR-382 showed no significant difference between the three studied groups, P > 0.05 (Table 1).

Table 1

miRNAs expressions among T2DM patients with and without MCI and non-diabetic normal cognitive individuals.

Mi- RNA	Non-diabetic normal cognitive individuals	T2DM patients’ cognitive function
		Normal Cognition	MCI	P value between the 3 groups
	Median (Q)	Median (Q)	Median (Q)
miR- 128	0.9 (0.3:2.4)	0.8 (0.3:1.8)	1.2 (0.5:2.1)	0.434
miR-132	1.2 (0.5:2.9) αb	1.1 (0.4:2.9)	2.0 (0.7:5.0) αb	0.036
miR-874	1.3 (0.4:3.2)	5.0 (1.6:6.3) ac	5.0 (2.4:6.5) bc	< 0.001
miR-134	0.6 (0.1:1.8)	0.8 (0.2:1.9)	0.6 (0.2:2.0)	0.227
miR-323	0.4 (0.1:1.6)	0.5 (0.1:1.5)	0.3 (0.1: 2.1)	0.993
miR-382	0.3 (0.1:1.0)	0.5 (0.1:1.1)	0.5 (0.2:1.6)	0.108

Q 1st: 3rd quartile.

Significant difference between T2DM with MCI compared to diabetics and non diabetics with normal cognition, P < 0.05.

Significant difference between T2DM with MCI compared to non-diabetics normal cognition, P < 0.05.

Significant difference between normal cognition with T2DM compared to non-diabetics, P < 0.05.

Risk factors for MCI among T2DM patients

Socio-demographic and medical data related to MCI among T2DM patients were assessed. Table 2 shows that female sex, low level of education, insulin treatment, presence of sensory peripheral neuropathy are risk factors associated with MCI among T2DM patients.

Table 2

Risk factors for MCI among T2DM patients.

Variable	Total	Cognitive function		Odds Ratio (CI 95%)
	n = 163
		MCI (n = 59)	Normal (n = 104)
		n (%)	n (%)
Age in years
40–49	38	13 (34.2)	25 (65.8)	®
50–60	125	46 (36.8)	79 (63.2)	1.1 (0.5–2.4)
Gender
Males	65	16 (24.6)	49 (75.4)	®
Females	98	43 (43.9)	55 (56.1)	0.4 (0.2–0.8)*
Education
Secondary	75	37 (49.3)	38 (50.7)	21.4 (2.7–167.2)**
University	65	21 (32.3)	44 (67.7)	10.5 (1.3–83.2)
Master/MD	23	1 (4.3)	22 (95.7)	®
Smoking
Non smokers	127	46 (36.2)	81 (63.8)	®
Smokers	36	13 (36.1)	23 (63.9)	1.0 (0.5–2.2)
Obesity
Obese	100	38 (38.0)	62 (62.0)	1.2 (0.6–2.4)
Non obese	63	21 (33.3)	42 (66.7)	®
Family history of Alzheimer
Yes	17	6 (35.3)	11 (64.7)	1.0 (0.34–2.7)
No	146	53 (36.3)	93 (63.7)	®
Hypertension
Yes	78	29 (37.2)	49 (62.8)	1.1 (0.6–2.1)
No	85	30 (35.3)	55 (64.7)	®
Duration of diabetes
≥ 10 years	68	25 (36.8)	43 (63.2)	1.0 (0.5–2.0)
< 10 years	95	34 (35.8)	61 (64.2)	®
Treatment received
Insulin	32	12 (37.5)	20 (56.3)	1.1 (0.5–2.4)
Oral hypoglycemic	131	47 (35.9)	84 (74.4)
Regular DM medication
Compliant	124	44 (35.5)	80 (64.5)	®
Not compliant	39	15 (38.5)	24 (61.5)	1.0 (0.4–1.9)
Hypoglycemia
Yes	84	31 (36.9)	53 (63.1)	1.1 (0.6–2.0)
No	79	28 (35.4)	51 (64.6)	®
PN
Yes	105	39 (37.1)	66 (62.9)	1.1 (0.5–2.2)
No	58	20 (34.5)	38 (65.5)	®
HbA1c% (mean±SD)	163	7.7±1.8	8.1±1.8	0.171
T.C mg/dl (mean±SD)	163	203.5± 45.5	201.4 ±45.8	0.777
Triglycerides mg/dl (mean±SD)	163	134.8±83.8	134.1±67.0	0.949
HDL mg/dl (mean±SD)	163	43.6±14.5	40.7±10.7	0.149
LDL mg/dl (mean±SD)	163	133.9±34.8	135.5±39.8	0.801

*P <0.05

** P <0.01, CI: Confidence Interval, ®: reference group, MCI: mild cognitive impairment, PN: peripheral neuropathy, TC: total cholesterol, HDL: high density lipoprotein, LDL: low density lipoprotein.

Table 3 presents logistic regression analysis for predicting the risk of MCI using socioeconomic, laboratory analysis, and miRNA expressions among T2DM patients. It revealed that higher miR- 132 expression, female gender, and below postgraduate education were the significant predicting factors for MCI among T2DM patients (P<0.05).

Table 3

Logistic regression analysis for predicting the risk of MCI among T2DM patients.

Variable	Adjusted Odds Ratio	95% CI	P value
	(AOR)
Gender
Males	®
Females	2.1	1.0–4.3	0.05
Education
Postgraduate	®
University education	9.5	1.2–75.6	0.034
Non-university education	19.4	2.5–152.8	0.005
miR-132	1.17	1.0–1.3	0.012
Constant	0.383		< 0.001

CI: confidence interval; ®: reference group.

Variables entered in model 1: age, gender, education, DM treatment, DM duration, hypoglycemia, hypertension, and in model 2: miR128, miR132, miR874, miR134, miR323, miR382.

Diagnostic performance of miR-128, miR-132 miR-874, miR-134, miR-323, and miR-382 for MCI in T2DM patients

ROC curves for studied miRNAs are presented in Fig 1. The AUC with sensitivity, specificity, and accuracy are presented in Table 4. miR-132 was the only biomarker that significantly differentiates T2DM patients with MCI from those with normal cognition with 72.3% sensitivity, 56.2% specificity, and 63.8% accuracy (P < 0.05).

Fig 1

Receiver-Operating Characteristic (ROC) curve of miR128, miR132, miR874, miR134, miR323, miR382 to evaluate their diagnostic value for MCI among T2DM patients.

Table 4

Diagnostic performance of studied miRNAs for detecting MCI among T2DM patients.

miRNAs	AUC	Sensitivity	Specificity	Accuracy	P-value
miR-128	0.571 (CI: 0.473–0.669)	61.70%	61.70%	61.90%	0.159
miR-132	0.627 (CI: 0.531–0.724)	72.30%	56.20%	63.80%	0.012*
miR-874	0.495 (CI: 0.396–0.593)	82.60%	24.70%	45.70%	0.916
miR-134	0.505 (CI: 0.406–0.604)	53.30%	50.00%	51.20%	0.917
miR-323	0.488 (CI: 0.387–0.589)	61.90%	50.20%	54.70%	0.816
miR-382	0.573 (CI: 0.474–0.672)	72.10%	42.50%	53.40%	0.149

*P <0.05; CI: confidence interval.

Discussion

The prevalence of diabetes and MCI are increasing worldwide partially due to the increase in the ageing population and lifestyle choices [12]. Previous studies reported associations of cognitive impairment and/or dementia with T2DM [6,13]

In the present study, MCI was detected among 36.2% of T2DM patients, which is much higher than the percrntage of MCI (7.5%) that was reported among healthy employee [14]. The association of cognitive impairment with T2DM might be related to insulin resistance as insulin receptors are widely distributed throughout the brain. Hyperinsulinemia that precedes or accompanies T2DM increases concentrations of amyloid β through inhibiting its brain clearance. Hyperinsulinemia that precedes or accompanies T2DM increases concentrations of amyloid β peptide (Aβ) through inhibiting its brain clearance. Insulin degrading enzyme (IDE) is responsible for degrading the Aβ as well degrading insulin [15]. IDE is the primary regulator of Aβ in both neurons and glia. Hyperinsulinemia acts as a competitive substrate for this enzyme with Aβ leading to its accumulation forming insoluble plaques [16]. Aβ is one of the main causes of neuronal death during of AD [17]. In the brains of AD and patients with MCI, Aβ have been shown to correlate with rapid cognitive decline [18]. Furthermore, hyperinsulinemia increases plasma and cerebrospinal fluid (CSF) concentrations of interleukin-6 and tumor necrosis factor alpha. All these mechanisms induce neuronal loss, amyloid beta plaques, and neurofibrillary tangles [19].

miRNAs have a significant role in the development of the CNS and in the etiology of many brain pathologies. They have regulatory role in learning and memory function and have an effect on cognition in the normal and diseased brain [20]. MCI and early AD are characterized by destruction of neurite and synapse [21]. miR-132 is widely distributed in the brain and plays a role in regulating neuronal differentiation, maturation and functioning, in adition it participates in axon growth, neural migration and plasticity [22]. Pichler and co-workers [23] reported early and great involvement of miR-132 and miR-212 in the pathogenesis of AD and further stressing on the primarily neuronal origin of these miRNAs. In the present study, The median miR-132 expression was significantly higher among T2DM patients with MCI compared to those with normal cognition as well as normal non-diabetic cognitive individuals, P< 0.05. Logistic regression analysis showed that higher miR-132 expression was a significant predicting risk factor for MCI among T2DM patients, with AOR 1.2 (95% CI 1.0–1.3). It differentiates significantly T2DM patients with MCI from those with normal cognition with 72.3% sensitivity, 56.2% specificity, and 63.8% accuracy. Similarly, Xie and co-workers [24] reported significant upregulation of miR-132 in MCI patients’ serum compared with control group. A systematic review done by Wu and co-workers [25] stated that out of the 8 MCI studies, only one miRNA, plasma miR-132, was consistently upregulated in three independent studies. Of the studies that reported diagnostic accuracy data, the majority of miRNA panels and individual miRNAs had a sensitivity and specificity greater than 75%. On the other hand, the knockout of miR-132 in mice was reported to impair learning and memory [26].

El Fatimy and co-workers [27] suggested that miR-132 is a master regulator of neuronal health and miR-132 supplementation could be of therapeutic benefit for the treatment of Tau-associated neurodegenerative disorders. They demonstrated that miR-132 protects primary mouse and human wild-type neurons and more vulnerable Tau-mutant neurons against Aβ and glutamate excitotoxicity. It reduces the level of total, phosphorylated, acetylated, and cleaved forms of Tau implicated in tauopathies, enhances neurite elongation and branching, and decreases neuronal death. Bekris and co-workers [28] assessed five miRNAs including miR-132 in CSF, plasma (obtained during life), cerebellum, and hippocampus (obtained at autopsy). They reported that expressions of these miRNAs in the CSF did not correlate with their expressions in the plasma. This may suggest differences in the expressions of these miRNAs according to the studied tissue type. A study done on transgenic mice showed enhance spatial learning with slight over-expression of hippocampal miR-132. While, with more than three folds overexpression of miR-132 impairs learning. They concluded that miR-132 acting as a key activity-dependent regulator of cognition, which means that the miR-132 expression must be sustained within certain range to ensure normal learning and memory formation [29]. Another study reported an initial increase of miR-132 levels was detected during early AD Braak stages I–II in the human prefrontal cortex, which contrasts with the significant decrease seen at more advanced stages of the disease [30]. Hansen and co-workers [29] found that cognitive capacity is tightly regulated by miR-132 and that physiological levels of miR-132 enhance cognition, whereas supra-physiological levels of the miRNA lead to cognitive deficits. Moreover, overexpression (~3-folds) of miR-132 leads to profound cognitive deficits. Together, these data indicate that miR- 132 plays a key role in shaping cognitive capacity.

miR-128 was reported to be overexpressed in AD patients [31]. In the present study, plasma miR-128 expression was found insignificantly higher in T2DM patients with MCI compared to T2DM patients and non diabetic individuals with normal cognitive functions. This may be explained by the high score of ACE III among T2DM with MCI (mean:81.5) which could indicates that MCI was not severe or was at early stage. Moreover, MÜller and co-workers [32] reported increase expression of miR-128 in the hippocampus in an intermediate stages of AD patients and to be downregulated in late stages of AD patients. In cell cultures, inhibition of miR-128 decreases Aβ-mediated cytotoxicity through inactivation of the NF-κB pathway [31].

miR-874 is involved in axonogenesis, neurotransmitter secretion, dendrite morphogenesis, synaptogenesis, synaptic transmission, and synaptic vesicle exocytosis [33]. Interestingly, in the present study the median miR-874 was overexpressed in T2DM patients with or without MCI compared to non diabetic individuals (P< 0.001), which may indicate its potential role in T2DM. miR-874 was found to be related to fat deposition through promoting insulin synthesis [34]. Moreover, miR-874 was found to be significantly correlated with BMI z-score among overweight/low-grade obesity children and adolescents, but not correlated with the levels of glucose, glycated hemoglobin, total cholesterol and HDL [35]. Additionally, miR-874 is transcriptionally controlled by FoxO3a, which is implicated in insulin/insulin-like growth factor signaling with its effect on gene expression, usually in the opposite direction as insulin and IGF-1 [36]. Similar to the current study, miR-874 expression was not found to be associated with MCI among healthy employee [14].

The current study revealed no significant difference in the median expression of miR-134 between T2DM patients with and without MCI and/or controls, P > 0.05. While Sheinerman and co-workers [9] reported higher levels of the miR-134 in MCI plasma patients compared to controls with 86% sensitivity and 82% specificity. miR‐134, is a brain‐specific miRNA that has been shown to be upregulated in AD patient brain samples [37]. miR-134 is localized to the synapto-dendritic compartment of rat hippocampal neurons and inhibits neurite growth and local protein synthesis at the synapses [38]. Gao and co-workers [39] reported that miR-134 mediates late long term potentiation (LTP) and synaptic plasticity through the Sirtuin1- cAMP-response-element binding protein (CREB) and brain-derived neurotrophic factor (BDNF) pathway in the hippocampus. miR‐134 post‐transcriptionally regulates the expression of CREB and BDNF in AD cases [40]. CREB and BDNF are two important plasticity-related proteins that are involved in synaptic plasticity and memory formation [41].

miR-323 is enriched in human pancreatic β compared to α-cells [42] and is considered as diagnostic and prognostic biomarker of beta-cell dysfunction [43]. Moreover, it is a biomarker in inflammatory and immune responses and was found to be associated with the pathogenesis of many diseases as Alzheimer's disease, rheumatoid arthritis, and ectopic pregnancy [44]. In the current study, median miR-323 expression in T2DM patients with and without MCI was slightly higher compared to normal cognitive controls (P >0.05). Similarly, Kumar and co-workers [45], by using RT-qPCR miRNA assay, they could not confirm the differential expression of plasma miR-323 between AD patients and healthy controls.

miR-382 is present in synaptoneurosomes of cortex, hippocampus and cerebellum [46] and was detected in the brain of some neurological disorders [47]. The current study revealed that there was no significant difference of median expression of miR-382 between the two T2DM patient groups and/or controls, P > 0.05. Rani and co-workers [48] stated that level of miR-382 increased with increasing age but not related to MoCA cognitive test score. Wang and co-workers [49] reported negative correlation between expression of miR-382 in grey matter and the density of early AD lesions subtypes (diffuse plaques, neuritic plaques, and neurofibrillary tangles). While, Sheinerman and co-workers [9] reported higher levels of the miR-134 in MCI plasma patients compared to controls.

A recent systematic review revealed that several miRNAs showed an ability to differentiate between MCI from healthy controls and MCI from AD patients, with modest to high sensitivity and specificity. However, the results of these studies were not always consistent and no consensus has yet been reached. Variations among studies could be due to different reasons including sample size which is widely variable across different studies, different criteria for selection of study participants, differences to define cases and controls, variation of technical procedures used, differences in miRNAs selection and in statistical analysis used [50].

In the current study, logistic analysis revealed that the significant conventional risk factors for predicting MCI among T2DM patients were female gender (AOR 2.1: 95% CI 1.0–4.3) and those with secondary and university education compared to postgraduates (AOR 19.4: 95% CI 2.5–152.8 and 9.5: 95% CI 1.2–75.6, respectively). The association of lower level of education with MCI among T2DM patients may be due to lack of brain stimulation acquired from continuous education upgrading. The higher prevalence of MCI among females may be related to their lower education level. It was reported that participants with normal cognitition had significantly higher educational level than those with MCI, with reduced risk of developing MCI and AD [51,52]. Several studies reported that longer duration of T2DM is associated with cognitive decline [53,54]. However, the present study did not detect such association, this might be due to delayed diagnosis of T2DM as most of the studied patients discovered the presence of diabetes accidently.

Some limitations in the current study deserve consideration. Baseline cognitive function scores were not available, which could have helped in comparing the effect of duration on the cognitive function over a time period. In addition, there are other brain-enriched miRNAs which were not assessed in the current study and may be useful as possible biomarkers in the future, computed tomography of the brain was not available and a group of non diabetic patients with MCI were not included to know if the studid miRANs are specific for MCI with T2DM or not.

In conclusion, MCI affects nearly one-third of adult patients with T2DM. A significantly over expression of miR-132 was detected among T2DM with MCI compared to those with normal cognition with sensitivity and specificity < 75%. Other studied miRNAs had lower sensitivity and specificity for detecting MCI among T2DM patients. Therefore, additional studies and extra work are recommended to illuminate their roles as potential biomarkers for MCI.

(XLSX)

Click here for additional data file.

1 Jun 2020

PONE-D-20-12036

Plasma microRNAs biomarkers in mild cognitive impairment among patients with type 2 diabetes mellitus

PLOS ONE

Dear Dr. Salama,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration by 2 Reviewers and an Academic Editor, all of the critiques of both Reviewers must be addressed in detail in a revision to determine publication status. If you are prepared to undertake the work required, I would be pleased to reconsider my decision, but revision of the original submission without directly addressing the critiques of the two Reviewers does not guarantee acceptance for publication in PLOS ONE. If the authors do not feel that the queries can be addressed, please consider submitting to another publication medium. A revised submission will be sent out for re-review. The authors are urged to have the manuscript given a hard copyedit for syntax and grammar.

Please submit your revised manuscript by November, 2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Stephen D. Ginsberg, Ph.D.

Section Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4. Please include a caption for each figure.

==============================

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this study, Iman I Salama et al reports that plasma expression of miR-132 was significantly higher in T2DM patients with MCI compared to those without MCI and to normal cognitive healthy subjects.

The cognitive impairment associated with diabetes is a world-wide problem. The article is meaningful because there are no reliable biomarkers for the patients of MCI with T2DM. However, there are several issues that need to be addressed.

1) In the study, the cognitive functions of normal cognitive healthy subjects and T2DM were assessed by the ACE III test, and the score less than 88 was diagnosed as MCI. Authors mentioned that the ACE III score of T2DM patients ranged from 69 to 100, however each score of T2DM groups with and without MCI was not shown. Authors should show the ACE III score of each group of T2DM patients as well as those of cognitive normal subjects.

2) How 163 participants were diagnosed as T2DM? Were they diagnosed by HbA1c and/or blood glucose level? The enrollment criteria of T2DM should be mentioned. In the paper, authors state that 32 of T2DM patients were taking insulin and the rest of patients (n=131) were taking oral hypoglycemic drugs (described in lines 153-154). However, the number of patients received treatments of insulin or oral hypoglycemic was 32 and 117, respectively as shown in Table 2. Please explain this discrepancy.

3) In the paper, the age, sex and education were matched between cognitive normal healthy subjects and T2DM patients (described in lines 82-83). Although the results of age and sex were mentioned in lines 150-152, authors have not shown whether the education level was matched. As shown in Table 2 and 3, the education level seems to be an important factor for the prediction of MCI. Thus, the comparison of education level between control and T2DM patients should be demonstrated.

4) Among the expression of miRNAs including miR-128, miR-132, miR-874, miR-134, miR-323 and miR-382, the expression of miR-132 was significantly higher in T2DM patients with MCI compared to those without MCI. Authors discuss the involvement of miR-128 and miR-874 in addition to miR-132, however there were no implications about the expression of miR-134, miR-323 and miR-382. Please discuss about these miR-134, miR-323 and miR-382 expressions.

5) Throughout the paper, there were many typographical errors such as “miRAs” in line 295. Please correct these wrong notations.

Reviewer #2: The manuscript PONE-D-20-12036 by Salama and colleagues explores the role of several plasma circulating miRNAs to assess their potential as a biomarkers of Mild Cognitive Impairment (MCI), among a population of Type 2 Diabetic patients. The authors focused on the analysis of previous miRNAs known to be associated with MCI. Their results show a significant correlation with high levels of circulating plasma miR-132 in T2D patients with MCI compared to patients without MCI or cognitive healthy individuals. Overall, the work presented by Salama and colleagues is of interest, well written and consistent. However, I recommend a few changes that would improve the quality of the manuscript.

Main points

1. The authors stated that total RNA extracted from plasma was measured with Nanodrop spectrophotometer. Could the authors indicate the amount of plasma RNA from plasma used for retro-transcription to perform miRNA detection? Also, I wonder if the authors were able to analyze the quality and concentration of small RNA by Bioanalyzer or by another alternative method.

2. While explaining the association with T2D with cognitive impairment the authors stated: “Hyperinsulinemia that precedes or accompanies T2DM increases concentrations of amyloid � through inhibiting its brain clearance.” (Line 211-212). Although a reader from the field will probably interpret this sentence easily, the authors might want to make this clear here by adding that amyloid � peptide is one of the main causes of neuronal death during of AD, which is known to be strongly associated with T2DM.

3. Finally, could the authors discuss the possible reason behind the increase in miR-132 in plasma and its potential source? This will maybe clarify the contradictory effect of high levels of miR-132 on MCI, since it is described in the literature that miR-132 exerts a number of beneficial neurolophysiological effects both in human and in mice.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

==============================

27 Jun 2020

Reply to the Reviewer Comments on the manuscript PONE-D-20-12036

We want to express our appreciation to the reviewers for their valuable comments and remarks which added a lot to the manuscript.

All corrections mentioned below are presented in the revised and in the track changed manuscript files. However, to indicate the site of the corrections done, lines mentioned here are presented in the track changed manuscript file.

Reviewer #1: In this study, Iman I Salama et al reports that plasma expression of miR-132 was significantly higher in T2DM patients with MCI compared to those without MCI and to normal cognitive healthy subjects.

The cognitive impairment associated with diabetes is a world-wide problem. The article is meaningful because there are no reliable biomarkers for the patients of MCI with T2DM. However, there are several issues that need to be addressed.

1) In the study, the cognitive functions of normal cognitive healthy subjects and T2DM were assessed by the ACE III test, and the score less than 88 was diagnosed as MCI. Authors mentioned that the ACE III score of T2DM patients ranged from 69 to 100, however each score of T2DM groups with and without MCI was not shown. Authors should show the ACE III score of each group of T2DM patients as well as those of cognitive normal subjects.

Thank you Professor for this valuable comment. We added the following paragraph from line 168 to line 172

"The mean score of ACE III was significantly lower among T2DM patients with MCI (81.5±4.5) compared to those with normal cognition (91.5±3.1), P < 0.001. While, the mean score of ACE III was significantly higher among cognitive normal individuals (93.7 ± 3.0) compared the T2DM patients with and without MCI, P < 0.001".

2) How 163 participants were diagnosed as T2DM? Were they diagnosed by HbA1c and/or blood glucose level? The enrollment criteria of T2DM should be mentioned. In the paper, authors state that 32 of T2DM patients were taking insulin and the rest of patients (n=131) were taking oral hypoglycemic drugs (described in lines 153-154). However, the number of patients received treatments of insulin or oral hypoglycemic was 32 and 117, respectively as shown in Table 2. Please explain this discrepancy.

a) Thank you Professor for this valuable comment. T2DM patients were already diagnosed as T2DM and were receiving anti-diabetics drugs, either insulin or oral hypoglycemic drugs. HbA1c was assessed for detecting the relation between HbA1c level and cognitive function.

We added and rephrased the following paragraph from line 77 to line 82

"Patients were already diagnosed as T2DM and were receiving anti-diabetics drugs, either insulin or oral hypoglycemic drugs. All patients were literate and were able to complete the tests of cognitive function. T2DM patients with history of head trauma, stroke, transient ischemic attack, brain tumor, epilepsy, psychiatric disease, cardiac or liver failure, history of thyroid disease, visual or hearing disabilities, and acute or chronic infection were excluded."

b) Yes, Professor you are right. This was a typographical error. Already, the total number T2DM patients for this raw in table 2 was 84 + 47=131 and not 117 as wrongly written. We corrected it to 131.

3) In the paper, the age, sex and education were matched between cognitive normal healthy subjects and T2DM patients (described in lines 82-83). Although the results of age and sex were mentioned in lines 150-152, authors have not shown whether the education level was matched. As shown in Table 2 and 3, the education level seems to be an important factor for the prediction of MCI. Thus, the comparison of education level between control and T2DM patients should be demonstrated.

Yes Professor, you are right. We added the following paragraph from line 162 to line 165.

"The percentages of T2DM patients having secondary, university and post graduate education were 46%, 39.9%, and 14.1% compared to 41.3%, 42.2% and 16.5% respectively among non-diabetic normal cognitive individuals, P= 0.716."

4) Among the expression of miRNAs including miR-128, miR-132, miR-874, miR-134, miR-323 and miR-382, the expression of miR-132 was significantly higher in T2DM patients with MCI compared to those without MCI. Authors discuss the involvement of miR-128 and miR-874 in addition to miR-132, however there were no implications about the expression of miR-134, miR-323 and miR-382. Please discuss about these miR-134, miR-323 and miR-382 expressions.

Thank you Professor for this valuable comment. We added the following paragraphs to discuss the mentioned miRNAs and the references were merged with the original manuscript references. We added the following paragraphs from line 301 to line 329

"The current study revealed no significant difference in the median expression of miR-134 between T2DM patients with and without MCI and/or controls, P > 0.05. While Sheinerman and co-workers (9) reported higher levels of the miR-134 in MCI plasma patients compared to controls with 86% sensitivity and 82% specificity. miR‐134, is a brain‐specific miRNA that has been shown to be upregulated in AD patient brain samples (37). miR-134 is localized to the synapto-dendritic compartment of rat hippocampal neurons and inhibits neurite growth and local protein synthesis at the synapses (38). Gao and co-workers (39) reported that miR-134 mediates late long term potentiation (LTP) and synaptic plasticity through the Sirtuin1- cAMP-response-element binding protein (CREB) and brain-derived neurotrophic factor (BDNF) pathway in the hippocampus. miR‐134 post‐transcriptionally regulates the expression of CREB and BDNF in AD cases (40). CREB and BDNF are two important plasticity-related proteins that are involved in synaptic plasticity and memory formation (41).

miR-323 is enriched in human pancreatic β compared to α-cells (42) and is considered as diagnostic and prognostic biomarker of beta-cell dysfunction (43). Moreover, it is a biomarker in inflammatory and immune responses and was found to be associated with the pathogenesis of many diseases as Alzheimer's disease, rheumatoid arthritis, and ectopic pregnancy (44). In the current study, median miR-323 expression in T2DM patients with and without MCI was slightly higher compared to normal cognitive controls (P >0.05). Similarly, Kumar and co-workers (45), by using RT-qPCR miRNA assay, they could not confirm the differential expression of plasma miR-323 between AD patients and healthy controls.

miR-382 is present in synaptoneurosomes of cortex, hippocampus and cerebellum (46) and was detected in the brain of some neurological disorders (47). The current study revealed that there was no significant difference of median expression of miR-382 between the two T2DM patient groups and/or controls, P > 0.05. Rani and co-workers (48) stated that level of miR-382 increased with increasing age but not related to MoCA cognitive test score. Wang and co-workers (49) reported negative correlation between expression of miR-382 in grey matter and the density of early AD lesions subtypes (diffuse plaques, neuritic plaques, and neurofibrillary tangles). While, Sheinerman and co-workers (9) reported higher levels of the miR-134 in MCI plasma patients compared to controls."

5) Throughout the paper, there were many typographical errors such as “miRAs” in line 295. Please correct these wrong notations.

Thank you Professor, you are right. The manuscript has been thoroughly revised and edited.

Reviewer #2: The manuscript PONE-D-20-12036 by Salama and colleagues explores the role of several plasma circulating miRNAs to assess their potential as a biomarkers of Mild Cognitive Impairment (MCI), among a population of Type 2 Diabetic patients. The authors focused on the analysis of previous miRNAs known to be associated with MCI. Their results show a significant correlation with high levels of circulating plasma miR-132 in T2D patients with MCI compared to patients without MCI or cognitive healthy individuals. Overall, the work presented by Salama and colleagues is of interest, well written and consistent. However, I recommend a few changes that would improve the quality of the manuscript.

1. The authors stated that total RNA extracted from plasma was measured with Nanodrop spectrophotometer. Could the authors indicate the amount of plasma RNA from plasma used for retro-transcription to perform miRNA detection? Also, I wonder if the authors were able to analyze the quality and concentration of small RNA by Bioanalyzer or by another alternative method.

a) Yes Professor, 2 µl of RNA were reverse-transcribed to cDNA

b) In the current study we used NanoDrop to assess concentration and purity of isolated RNA. While, miRNA expressions was assessed using Quantitative real-time PCR assay according to the manufacture instructions of the TaqMan™ Advanced miR cDNA Synthesis Kit, Catalog Number A25576). (Applied Biosystems, Foster City, CA, USA). We did not use Bioanalyzer or any further alternative method.

We rephrasing the following paragraph from line 126 to line 131

"The concentration and purity of isolated RNA were evaluated by NanoDrop 1000 (Nanodrop, Wilmingtion, Delaware, USA) using 1 µl of RNA based on the absorbance measurements at wavelengths of 260 and 280 nm. Samples with 260/280 ratios of ~2.0 is generally accepted as “pure” for RNA. Then, 2 µl of RNA were reverse-transcribed to cDNA using TaqMan™ Advanced miR cDNA Synthesis Kit, Catalog Number A25576). (Applied Biosystems, Foster City, CA, USA).

2. While explaining the association with T2D with cognitive impairment the authors stated: “Hyperinsulinemia that precedes or accompanies T2DM increases concentrations of amyloid � through inhibiting its brain clearance.” (Line 211-212). Although a reader from the field will probably interpret this sentence easily, the authors might want to make this clear here by adding that amyloid � peptide is one of the main causes of neuronal death during of AD, which is known to be strongly associated with T2DM.

Thank you Professor for this valuable comment. We added the following paragraph from line 227 to line 235

"Hyperinsulinemia that precedes or accompanies T2DM increases concentrations of amyloid β through inhibiting its brain clearance. Hyperinsulinemia that precedes or accompanies T2DM increases concentrations of amyloid β peptide (Aβ) through inhibiting its brain clearance. Insulin degrading enzyme (IDE) is responsible for degrading the Aβ as well degrading insulin (15). IDE is the primary regulator of Aβ in both neurons and glia. Hyperinsulinemia acts as a competitive substrate for this enzyme with Aβ leading to its accumulation forming insoluble plaques (16). Aβ is one of the main causes of neuronal death during of AD (17). In the brains of AD and patients with MCI, Aβ have been shown to correlate with rapid cognitive decline (18)."

3. Finally, could the authors discuss the possible reason behind the increase in miR-132 in plasma and its potential source? This will maybe clarify the contradictory effect of high levels of miR-132 on MCI, since it is described in the literature that miR-132 exerts a number of beneficial neurolophysiological effects both in human and in mice.

Yes professor, Thank you for this valuable comment. We added the following two paragraphs:

from line 244 to line 246

"Pichler and co-workers (23) reported early and great involvement of miR-132 and miR-212 in the pathogenesis of AD and further stressing on the primarily neuronal origin of these miRNAs."

from line 273 to line 280.

"An initial increase of miR-132 levels was detected during early AD Braak stages I–II in the human prefrontal cortex, which contrasts with the significant decrease seen at more advanced stages of the disease (30). Hansen and co-workers (29) found that cognitive capacity is tightly regulated by miR-132 and that physiological levels of miR-132 enhance cognition, whereas supra-physiological levels of the miRNA lead to cognitive deficits. Moreover, overexpression (~3-folds) of miR-132 leads to profound cognitive deficits. Together, these data indicate that miR- 132 plays a key role in shaping cognitive capacity."

Submitted filename: Response to Reviewers.doc

Click here for additional data file.

8 Jul 2020

Plasma microRNAs biomarkers in mild cognitive impairment among patients with type 2 diabetes mellitus

PONE-D-20-12036R1

Dear Dr. Salama,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Stephen D. Ginsberg, Ph.D.

Section Editor

PLOS ONE

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

14 Jul 2020

PONE-D-20-12036R1

Plasma microRNAs biomarkers in mild cognitive impairment among patients with type 2 diabetes mellitus

Dear Dr. Salama:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Stephen D. Ginsberg

Section Editor

PLOS ONE